Ischaemiareperfusion injury impairs tissue plasminogen activator release in man

European Heart Journal

Volumn 33, Issue 15, 2012, Pages 1920-1927

  Pedersen, Christian M ^a,b   Barnes, Gareth ^a   Schmidt, Michael R ^b   Botker, Hans Erik ^b   Kharbanda, Rajesh K ^c   Newby, David E ^a   Cruden, Nicholas L ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Endogenous fibrinolysis; Endothelium; Ischaemiareperfusion; Preconditioning; Substance P

Indexed keywords

ACETYLCHOLINE; SUBSTANCE P; TISSUE PLASMINOGEN ACTIVATOR; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; VASODILATOR AGENT;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME RELEASE; FIBRINOLYSIS; FOREARM BLOOD FLOW; HUMAN; HUMAN EXPERIMENT; ISCHEMIC PRECONDITIONING; LIMB ISCHEMIA; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY; VASCULAR ENDOTHELIUM; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY; VENOUS BLOOD; ANALYSIS OF VARIANCE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG EFFECT; FOREARM; LIGATION; METABOLISM; METHODOLOGY; PHYSIOLOGY; SECRETION (PROCESS); VASCULARIZATION;

ACETYLCHOLINE; ANALYSIS OF VARIANCE; BLOOD PRESSURE; CONSTRICTION; CROSS-OVER STUDIES; FIBRINOLYSIS; FOREARM; HUMANS; ISCHEMIC PRECONDITIONING; MALE; NEUROTRANSMITTER AGENTS; REPERFUSION INJURY; SUBSTANCE P; TISSUE PLASMINOGEN ACTIVATOR; VASODILATION; VASODILATOR AGENTS; YOUNG ADULT;

EID: 84864624313     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr380     Document Type: Article

References (37)

1. Tiefenbacher CP, Chilian WM, Mitchell M, DeFily DV. Restoration of endothelium-dependent vasodilation after reperfusion injury by tetrahydrobiopterin. Circulation 1996;94:1423-1429.
2. Kharbanda RK, Peters M, Walton B, Kattenhorn M, Mullen M, Klein N, Vallance P, Deanfield J, MacAllister R. Ischemic preconditioning prevents endothelial injury and systemic neutrophil activation during ischemia-reperfusion in humans in vivo. Circulation 2001;103:1624-1630.
3. Kharbanda RK, Mortensen UM, White PA, Kristiansen SB, Schmidt MR, Hoschtitzky JA, Vogel M, Sorensen K, Redington AN, MacAllister R. Transient limb ischemia induces remote ischemic preconditioning in vivo. Circulation 2002; 106:2881-2883.
4. Oliver JJ,Webb DJ, Newby DE. Stimulated tissue plasminogen activator release as a marker of endothelial function in humans. Arterioscler Thromb VascBiol 2005;25: 2470-2479.
5. Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 1999;340:1555-1564.
6. Newby DE, Wright RA, Labinjoh C, Ludlam CA, Fox KA, Boon NA, Webb DJ. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation 1999;99:1411-1415.
7. Robinson SD, Ludlam CA, Boon NA, Newby DE. Endothelial fibrinolytic capacity predicts future adverse cardiovascular events in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 2007;27:1651-1656.
8. Newby DE, McLeod AL, Uren NG, Flint L, Ludlam CA, Webb DJ, Fox KA, Boon NA. Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation 2001;103:1936-1941.
9. Aspelin T, Eriksen M, Lindgaard AK, Lyberg T, Ilebekk A. Cardiac fibrinolytic capacity is markedly increased after brief periods of local myocardial ischemia, but declines following successive periods in anesthetized pigs. J Thromb Haemost 2005;3:1947-1954.
10. Valen G, Eriksson E, Risberg B, Vaage J. Reactive oxygen intermediates and ischemia-reperfusion injury release tissue plasminogen activator from isolated rat hearts. Thromb Res 1993;71:113-121.
11. Winnerkvist A, Wiman B, Valen G, Vaage J. Release of tissue plasminogen activator during reperfusion after different times of ischaemia in isolated, perfused rat hearts. Thromb Res 1996;82:533-542.
12. Schoots IG, Levi M, van Vliet AK, Declerck PJ, Maas AM, van Gulik TM. Enhancement of endogenous fibrinolysis does not reduce local fibrin deposition, but modulates inflammation upon intestinal ischemia and reperfusion. Thromb Haemost 2004;91:497-505.
13. Roelofs JJ, Rouschop KM, Leemans JC, Claessen N, de Boer AM, Frederiks WM, Lijnen HR, Weening JJ, Florquin S. Tissue-type plasminogen activator modulates inflammatory responses and renal function in ischemia reperfusion injury. J Am Soc Nephrol 2006;17:131-140.
14. Treska V, Valenta J, Pecen L, Topolcan O. Endogenous fibrinolysis in patients with lower extremity ischemia. Ann Vasc Surg 2000;14:356-359.
15. Killewich LA, Gardner AW, Macko RF, Hanna DJ, Goldberg AP, Cox DK, Flinn WR. Progressive intermittent claudication is associated with impaired fibrinolysis. J Vasc Surg 1998;27:645-650.
16. Newby DE, Wright RA, Ludlam CA, Fox KA, Boon NA, Webb DJ. An in vivo model for the assessment of acute fibrinolytic capacity of the endothelium. Thromb Haemost 1997;78:1242-1248.
17. Garlid KD, Paucek P, Yarov-Yarovoy V, Murray HN, Darbenzio RB, D'Alonzo AJ, Lodge NJ, Smith MA, Grover GJ. Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+ channels. Possible mechanism of cardioprotection. Circ Res 1997;81:1072-1082.
18. Broadhead MW, Kharbanda RK, Peters MJ, MacAllister RJ. KATP channel activation induces ischemic preconditioning of the endothelium in humans in vivo. Circulation 2004;110:2077-2082.
19. Muldowney JA III, Painter CA, Sanders-Bush E, Brown NJ, Vaughan DE. Acute tissue-type plasminogen activator release in human microvascular endothelial cells: the roles of Galphaq, PLC-beta, IP3 and 5,6-epoxyeicosatrienoic acid. Thromb Haemost 2007;97:263-271.
20. Gudmundsdottir IJ, Lang NN, Boon NA, Ludlam CA, Webb DJ, Fox KA, Newby DE. Role of the endothelium in the vascular effects of the thrombin receptor (protease-activated receptor type 1) in humans. J Am Coll Cardiol 2008;51:1749-1756.
21. Zhong B, Wang DH. TRPV1 gene knockout impairs preconditioning protection against myocardial injury in isolated perfused hearts in mice. Am J Physiol Heart Circ Physiol 2007;293:H1791-H1798.
22. Newby DE, Sciberras DG, Mendel CM, Gertz BJ, Boon NA, Webb DJ. Intra-arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability. Br J Clin Pharmacol 1997;43:493-499.
23. Jaffe R, Dick A, Strauss BH. Prevention and treatment of microvascular obstruction-related myocardial injury and coronary no-reflow following percutaneous coronary intervention: a systematic approach. JACC Cardiovasc Interv 2010;3: 695-704.
24. Gibson CM, Karha J, Murphy SA, James D, Morrow DA, Cannon CP, Giugliano RP, Antman EM, Braunwald E. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol 2003;42:7-16.
25. Grines C, Patel A, Zijlstra F,Weaver WD, Granger C, Simes RJ. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. Am Heart J 2003;145:47-57.
26. Keeley EC, Boura JA, Grines CL. Primary angioplasty vs. intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361:13-20.
27. Nanobashvili J, Neumayer C, Fuegl A, Blumer R, Prager M, Sporn E, Polterauer P, Malinski T, Huk I. Development of 'no-reflow' phenomenon in ischemia/reperfusion injury: failure of active vasomotility and not simply passive vasoconstriction. Eur Surg Res 2003;35:417-424.
28. Heusch G, Kleinbongard P, Bose D, Levkau B, Haude M, Schulz R, Erbel R. Coronary microembolization: from bedside to bench and back to bedside. Circulation 2009;120:1822-1836.
29. Reffelmann T, Kloner RA. The no-reflow phenomenon: a basic mechanism of myocardial ischemia and reperfusion. Basic Res Cardiol 2006;101: 359-372.
30. Woo KS, Armiger LC, White HD, Norris RM. Can streptokinase produce beneficial effects additional to coronary recanalization? Quantitative microvascular analysis of critically injured reperfused myocardium. Microvasc Res 2000;60: 8-20.
31. Sezer M, Oflaz H, Goren T, Okcular I, Umman B, Nisanci Y, Bilge AK, Sanli Y, Meric M, Umman S. Intracoronary streptokinase after primary percutaneous coronary intervention. N Engl J Med 2007;356:1823-1834.
32. Okorie MI, Bhavsar DD, Ridout D, Charakida M, Deanfield JE, Loukogeorgakis SP, Macallister RJ. Postconditioning protects against human endothelial ischaemiareperfusion injury via subtype-specific KATP channel activation and is mimicked by inhibition of the mitochondrial permeability transition pore. Eur Heart J 2011;32:1266-1274.
33. Richard V, Kaeffer N, Tron C, Thuillez C. Ischemic preconditioning protects against coronary endothelial dysfunction induced by ischemia and reperfusion. Circulation 1994;89:1254-1261.
34. Laskey WK, Yoon S, Calzada N, Ricciardi MJ. Concordant improvements in coronary flow reserve and ST-segment resolution during percutaneous coronary intervention for acute myocardial infarction: a benefit of postconditioning. Catheter Cardiovasc Interv 2008;72:212-220.
35. Heusch G, Schulz R. Preservation of peripheral vasodilation as a surrogate of cardioprotection? The mechanistic role of ATP-dependent potassium channels and the mitochondrial permeability transition pore. Eur Heart J 2011;32: 1184-1186.
36. Brown NJ, Gainer JV, Murphey LJ, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor- dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation 2000;102:2190-2196.
37. Pedersen CM, Cruden NL, Schmidt MR, Lau C, Botker HE, Kharbanda RK, Newby DE. Remote ischemic preconditioning prevents systemic platelet activation associated with ischemia-reperfusion injury in humans. J Thromb Haemost 2011;9:404-407.